Christopher Reardon – VJRegenMed

Optimizing AAV vectors with AI

Simon Ng — Mon, 07 Feb 2022 17:06:03 +0000

Christopher Reardon, Dyno Therapeutics, Cambridge, MA, discusses using artificial intelligence (AI) to enhance the properties of adeno-associated virus (AAV) vectors. Whilst a vast number of changes to the capsid are possible, the advent of AI technology can refine the process to make productive alterations. The CapsidMap platform has enabled the optimization of AAV capsids, with the intention of using personalized AAV vectors for therapies instead of the standard AAV9 or AAV2 vectors. This interview took place at Advanced Therapies Week 2022.

Highlights from Advanced Therapies Week 2022

Simon Ng — Mon, 07 Feb 2022 17:06:01 +0000

Christopher Reardon, Dyno Therapeutics, Cambridge, MA, provides his highlights from Advanced Therapies Week 2022, including discussions relating to the development of fixed-bed bioreactors for adherent cell culture, which will enable the scaling-up of viral vector manufacturing. He additionally discusses improvements in the regulatory field, where authorities are streamlining the process for novel therapies, as well as improving the workplace environment for staff. This interview took place at Advanced Therapies Week 2022.

Clinical challenges in developing AAV-based gene therapies

Simon Ng — Tue, 01 Feb 2022 18:03:38 +0000

Adeno-associated virus (AAV) vectors have become pivotal in the clinical development of gene therapies. Christopher Reardon, Dyno Therapeutics, Cambridge, MA, describes challenges associated with using AAV vectors, including regulatory barriers. Despite a small number of gene therapies successfully being approved, the pathway for regulating this novel technology requires consolidation and optimization. This interview took place at Advanced Therapies Week 2022.